- Home
- HSII vs COLL Comparison
HSII vs COLL Comparison
Compare HSII & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- COLL
- Stock Information
- Founded
- HSII 1953
- COLL 2002
- Country
- HSII United States
- COLL United States
- Employees
- HSII N/A
- COLL N/A
- Industry
- HSII Diversified Commercial Services
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- COLL Health Care
- Exchange
- HSII Nasdaq
- COLL Nasdaq
- Market Cap
- HSII 904.6M
- COLL 958.8M
- IPO Year
- HSII 1999
- COLL 2015
- Fundamental
- Price
- HSII $47.93
- COLL $37.03
- Analyst Decision
- HSII Buy
- COLL Strong Buy
- Analyst Count
- HSII 2
- COLL 4
- Target Price
- HSII $49.00
- COLL $44.25
- AVG Volume (30 Days)
- HSII 95.6K
- COLL 380.6K
- Earning Date
- HSII 08-04-2025
- COLL 08-07-2025
- Dividend Yield
- HSII 1.25%
- COLL N/A
- EPS Growth
- HSII N/A
- COLL N/A
- EPS
- HSII 1.60
- COLL 1.06
- Revenue
- HSII $1,155,576,000.00
- COLL $707,007,000.00
- Revenue This Year
- HSII $6.41
- COLL $20.47
- Revenue Next Year
- HSII $2.65
- COLL $2.91
- P/E Ratio
- HSII $29.88
- COLL $35.07
- Revenue Growth
- HSII 9.00
- COLL 22.61
- 52 Week Low
- HSII $35.54
- COLL $23.23
- 52 Week High
- HSII $51.24
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- HSII 58.80
- COLL 69.53
- Support Level
- HSII $44.79
- COLL $29.70
- Resistance Level
- HSII $49.80
- COLL $38.24
- Average True Range (ATR)
- HSII 1.60
- COLL 1.23
- MACD
- HSII 0.34
- COLL 0.71
- Stochastic Oscillator
- HSII 61.29
- COLL 87.29
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.